{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T22:45:22Z","timestamp":1782686722499,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,28]]},"DOI":"10.7759\/cureus.111672","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T22:25:19Z","timestamp":1782685519000},"source":"Crossref","is-referenced-by-count":0,"title":["Lenvatinib-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Metastatic Clear Cell Renal Cell Carcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Nasong A","family":"Luginaah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aquila","family":"Akingbade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Climans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13010033","article-title":"Posterior reversible encephalopathy syndrome after lenvatinib therapy in a patient with olfactory neuroblastoma","volume":"13","author":"Tseng YJ","year":"2022","unstructured":"Tseng YJ, Chen CN, Hong RL, Kung WM, Huang AP. Posterior reversible encephalopathy syndrome after lenvatinib therapy in a patient with olfactory neuroblastoma. Brain Sci. 2022, 13:33. 10.3390\/brainsci13010033","journal-title":"Brain Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2114482","article-title":"Posterior reversible encephalopathy syndrome","volume":"388","author":"Geocadin RG","year":"2023","unstructured":"Geocadin RG. Posterior reversible encephalopathy syndrome. N Engl J Med. 2023, 388:2171-8. 10.1056\/NEJMra2114482","journal-title":"N Engl J Med"},{"key":"ref3","article-title":"Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images","volume":"23","author":"Covarrubias DJ","year":"2002","unstructured":"Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002, 23:1038-48.","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12245-026-01138-9","article-title":"Posterior reversible encephalopathy syndrome (PRES): a narrative review of pathophysiology, clinical insights, and advances in management","volume":"19","author":"Mourid MR","year":"2026","unstructured":"Mourid MR, Oweidat M, Abady E, et al.. Posterior reversible encephalopathy syndrome (PRES): a narrative review of pathophysiology, clinical insights, and advances in management. Int J Emerg Med. 2026, 19:48. 10.1186\/s12245-026-01138-9","journal-title":"Int J Emerg Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer R","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, et al.. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021, 384:1289-300. 10.1056\/NEJMoa2035716","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons M","year":"2016","unstructured":"Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016, 17:611-25. 10.1038\/nrm.2016.87","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline","volume":"40","author":"Rathmell WK","year":"2022","unstructured":"Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al.. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. J Clin Oncol. 2022, 40:2957-95. 10.1200\/JCO.22.00868","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101145","article-title":"Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer","volume":"9","author":"Faruque LI","year":"2014","unstructured":"Faruque LI, Lin M, Battistella M, et al.. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS One. 2014, 9:101145. 10.1371\/journal.pone.0101145","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Je Y","year":"2009","unstructured":"Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 2009, 10:967-74. 10.1016\/S1470-2045(09)70222-0","journal-title":"Lancet Oncol"},{"key":"ref10","article-title":"AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual","year":"2009","unstructured":"AJCC Cancer Staging Handbook. From the AJCC Cancer Staging Manual. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (ed): Springer, New York (NY); 2009."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25606","article-title":"Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review","volume":"9","author":"Chae YK","year":"2018","unstructured":"Chae YK, Chiec L, Adney SK, et al.. Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review. Oncotarget. 2018, 9:28281-9. 10.18632\/oncotarget.25606","journal-title":"Oncotarget"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9593-17","article-title":"Posterior reversible encephalopathy syndrome after lenvatinib therapy in a patient with anaplastic thyroid carcinoma","volume":"57","author":"Osawa Y","year":"2018","unstructured":"Osawa Y, Gozawa R, Koyama K, Nakayama T, Sagoh T, Sunaga H. Posterior reversible encephalopathy syndrome after lenvatinib therapy in a patient with anaplastic thyroid carcinoma. Intern Med. 2018, 57:1015-9. 10.2169\/internalmedicine.9593-17","journal-title":"Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1605","article-title":"Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer-a case report","volume":"5","author":"Abhishek M","year":"2022","unstructured":"Abhishek M, Renuka A, Ujjwal A, et al.. Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer-a case report. Cancer Rep (Hoboken). 2022, 5:1605. 10.1002\/cnr2.1605","journal-title":"Cancer Rep (Hoboken)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5812\/ijem-136900","article-title":"Posterior reversible encephalopathy syndrome as an adverse effect of lenvatinib in a patient with papillary thyroid carcinoma: a case report","volume":"21","author":"Buenaventura DC","year":"2023","unstructured":"Buenaventura DC, Vargas-Sierra H, Aristizabal-Henao N, Torres-Grajales JL, Aguilar-Londono C, Gutierrez-Restrepo J. Posterior reversible encephalopathy syndrome as an adverse effect of lenvatinib in a patient with papillary thyroid carcinoma: a case report. Int J Endocrinol Metab. 2023, 21:136900. 10.5812\/ijem-136900","journal-title":"Int J Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1079716","article-title":"Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer","volume":"12","author":"Matsuura Y","year":"2022","unstructured":"Matsuura Y, Nishida H, Kosaka T, et al.. Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer. Front Oncol. 2022, 12:1079716. 10.3389\/fonc.2022.1079716","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1487009","article-title":"Case Report: Posterior reversible encephalopathy syndrome after lenvatinib treatment for hepatocellular carcinoma","volume":"16","author":"Chen M","year":"2025","unstructured":"Chen M, Shen J, Jia R, et al.. Case Report: Posterior reversible encephalopathy syndrome after lenvatinib treatment for hepatocellular carcinoma. Front Pharmacol. 2025, 16:1487009. 10.3389\/fphar.2025.1487009","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco R","year":"2021","unstructured":"Velasco R, Villagr\u00e1n M, Jov\u00e9 M, et al.. Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol. 2021, 78:864-73. 10.1001\/jamaneurol.2021.0249","journal-title":"JAMA Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00232-7","article-title":"Posterior reversible encephalopathy syndrome: evolving insights in diagnosis, management, and outcomes","volume":"24","author":"Fugate JE","year":"2025","unstructured":"Fugate JE, Hawkes MA, Rabinstein AA. Posterior reversible encephalopathy syndrome: evolving insights in diagnosis, management, and outcomes. Lancet Neurol. 2025, 24:789-800. 10.1016\/S1474-4422(25)00232-7","journal-title":"Lancet Neurol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2244","article-title":"Endothelial function is impaired across the stages of the menopause transition in healthy women","volume":"97","author":"Moreau KL","year":"2012","unstructured":"Moreau KL, Hildreth KL, Meditz AL, Deane KD, Kohrt WM. Endothelial function is impaired across the stages of the menopause transition in healthy women. J Clin Endocrinol Metab. 2012, 97:4692-700. 10.1210\/jc.2012-2244","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/493224-lenvatinib-associated-posterior-reversible-encephalopathy-syndrome-in-a-patient-with-metastatic-clear-cell-renal-cell-carcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T22:25:20Z","timestamp":1782685520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/493224-lenvatinib-associated-posterior-reversible-encephalopathy-syndrome-in-a-patient-with-metastatic-clear-cell-renal-cell-carcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.111672","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,28]]}}}